Health economic impact of liquid biopsies in cancer management

Maarten J. IJzerman (Corresponding Author), A.M. Sofie Berghuis, Johann S. de Bono, Leon W.M.M. Terstappen

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
67 Downloads (Pure)

Abstract

Introduction: Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed.

Areas covered: This paper presents a health economic perspective of LBs in cancer management. We first briefly introduce the requirements in biomarker development and validation, illustrated for CTCs. Second, we discuss the state-of-art on the clinical utility of LBs in breast cancer in more detail. We
conclude with a future perspective on the clinical use and reimbursement of LBs

Expert commentary: A significant increase in clinical research on LBs can be observed and the results suggest a rapid change of cancer management. In addition to studies evaluating clinical utility of LBs, a smooth translation into clinical practice requires systematic assessment of the health economic benefits.This paper argues that (early stage) health economic research is required to facilitate its clinical use and to prioritize further evidence development.
Original languageEnglish
Pages (from-to)593-599
Number of pages7
JournalExpert review of pharmacoeconomics & outcomes research
Volume18
Issue number6
DOIs
Publication statusPublished - 7 Aug 2018

Fingerprint

Economics
Biopsy
Health
Circulating Neoplastic Cells
Neoplasms
Insurance Benefits
Tumor Biomarkers
Research
Biomarkers
Breast Neoplasms
DNA

Keywords

  • UT-Hybrid-D
  • Cancer
  • Circulating tumor cells
  • ctDNA
  • Health economics
  • Biomarker
  • Diagnostics
  • Liquid biopsies

Cite this

@article{bce87ec0bc4347cb907c4ae61bdf4aa7,
title = "Health economic impact of liquid biopsies in cancer management",
abstract = "Introduction: Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed.Areas covered: This paper presents a health economic perspective of LBs in cancer management. We first briefly introduce the requirements in biomarker development and validation, illustrated for CTCs. Second, we discuss the state-of-art on the clinical utility of LBs in breast cancer in more detail. Weconclude with a future perspective on the clinical use and reimbursement of LBsExpert commentary: A significant increase in clinical research on LBs can be observed and the results suggest a rapid change of cancer management. In addition to studies evaluating clinical utility of LBs, a smooth translation into clinical practice requires systematic assessment of the health economic benefits.This paper argues that (early stage) health economic research is required to facilitate its clinical use and to prioritize further evidence development.",
keywords = "UT-Hybrid-D, Cancer, Circulating tumor cells, ctDNA, Health economics, Biomarker, Diagnostics, Liquid biopsies",
author = "IJzerman, {Maarten J.} and Berghuis, {A.M. Sofie} and {de Bono}, {Johann S.} and Terstappen, {Leon W.M.M.}",
note = "Taylor & Francis deal",
year = "2018",
month = "8",
day = "7",
doi = "10.1080/14737167.2018.1505505",
language = "English",
volume = "18",
pages = "593--599",
journal = "Expert review of pharmacoeconomics & outcomes research",
issn = "1473-7167",
publisher = "Taylor & Francis",
number = "6",

}

Health economic impact of liquid biopsies in cancer management. / IJzerman, Maarten J. (Corresponding Author); Berghuis, A.M. Sofie; de Bono, Johann S.; Terstappen, Leon W.M.M.

In: Expert review of pharmacoeconomics & outcomes research, Vol. 18, No. 6, 07.08.2018, p. 593-599.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Health economic impact of liquid biopsies in cancer management

AU - IJzerman, Maarten J.

AU - Berghuis, A.M. Sofie

AU - de Bono, Johann S.

AU - Terstappen, Leon W.M.M.

N1 - Taylor & Francis deal

PY - 2018/8/7

Y1 - 2018/8/7

N2 - Introduction: Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed.Areas covered: This paper presents a health economic perspective of LBs in cancer management. We first briefly introduce the requirements in biomarker development and validation, illustrated for CTCs. Second, we discuss the state-of-art on the clinical utility of LBs in breast cancer in more detail. Weconclude with a future perspective on the clinical use and reimbursement of LBsExpert commentary: A significant increase in clinical research on LBs can be observed and the results suggest a rapid change of cancer management. In addition to studies evaluating clinical utility of LBs, a smooth translation into clinical practice requires systematic assessment of the health economic benefits.This paper argues that (early stage) health economic research is required to facilitate its clinical use and to prioritize further evidence development.

AB - Introduction: Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed.Areas covered: This paper presents a health economic perspective of LBs in cancer management. We first briefly introduce the requirements in biomarker development and validation, illustrated for CTCs. Second, we discuss the state-of-art on the clinical utility of LBs in breast cancer in more detail. Weconclude with a future perspective on the clinical use and reimbursement of LBsExpert commentary: A significant increase in clinical research on LBs can be observed and the results suggest a rapid change of cancer management. In addition to studies evaluating clinical utility of LBs, a smooth translation into clinical practice requires systematic assessment of the health economic benefits.This paper argues that (early stage) health economic research is required to facilitate its clinical use and to prioritize further evidence development.

KW - UT-Hybrid-D

KW - Cancer

KW - Circulating tumor cells

KW - ctDNA

KW - Health economics

KW - Biomarker

KW - Diagnostics

KW - Liquid biopsies

U2 - 10.1080/14737167.2018.1505505

DO - 10.1080/14737167.2018.1505505

M3 - Article

VL - 18

SP - 593

EP - 599

JO - Expert review of pharmacoeconomics & outcomes research

JF - Expert review of pharmacoeconomics & outcomes research

SN - 1473-7167

IS - 6

ER -